TICKERNERD
Menu
CNSYCNSYHealthcare · Biotechnology

CNSY Stock Forecast: Cerenome, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.33
−2.72% on the day

The 4 Wall Street analysts covering Cerenome, Inc. hold a median 12-month price target of $38 — +1512.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 17 of 100 as at 12 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$17.6M
Ticker Nerd rank
17 / 100
Median analyst target
$38
Analysts covering
4
Revenue$0.0
Operating income−$9.1M
Net income−$9.0M
Free cash flow−$7.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−22.0%
1M
−39.3%
YTD
−81.8%
1Y
−80.2%
From 52W high
−89.6%
From 52W low
0.0%
$2
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNSY stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Cerenome, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
17 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Accruals
53
Growth
42
Revisions
34
Value
28
Quality
27
Volatility
21
Issuance
18
Momentum
4

Size (89): Smaller than most of the companies we track.

Momentum (4): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNSY stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNSY, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26CNSYHigh $57Median $38Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $38High $57

The green dot is the last close — the median target sits +1512.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Sept 2026Ascendiant CapitalMaintainsBuy$57 → $43
8 June 2026Ascendiant CapitalMaintainsBuy$65 → $57
8 June 2026Ascendiant CapitalMaintainsBuy—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
31 Mar 2026D. Boral CapitalDowngradeHold—
19 Mar 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
11 Dec 2025D. Boral CapitalMaintainsBuy—
1 Dec 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
3 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025D. Boral CapitalMaintainsBuy—
21 Oct 2025D. Boral CapitalMaintainsBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
18 Sept 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNSY appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CNSY vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Cerenome, Inc. returned −80.2% against +17.5% for the S&P 500, dividends included.

CNSY vs S&P 500, last 12 monthsTotal return, rebased to 100
050100150Oct 25Jan 26Apr 26Jul 26CNSYS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNSY analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Cerenome, Inc. (CNSY) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.8×

Cheaper than 71% of US stocks

Price / sales
4.2×

Cheaper than 29% of US stocks

Price / book
3.1×

Cheaper than 32% of US stocks

EV / EBITDA
−0.4×

Cheaper than 63% of US stocks

Growth & margins
Revenue growth (YoY)
−70.4%

Higher than 3% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−2203.6%

Higher than 4% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−614.1%

Higher than 2% of US stocks

Return on assets
−135.4%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Cerenome, Inc. (CNSY) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Cerenome, Inc. has a market value of $17.6M and an enterprise value of $9.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0. The latest quarter shrank 70.4% year on year.

  • Net income over the same four quarters: −$26.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$23.5M.

  • Shares outstanding: 7.3M.

  • Trailing P/E: 0.8×; forward P/E: −0.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Cerenome, Inc. employs 28 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

CNSY vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNSYCerenome, Inc.$17.6M
17
NCELNewCelX Ltd.$17.7M
21
KTTAPasithea Therapeutics Corp.$17.7M
14
LPCNLipocine, Inc.$18.2M
38
NIKINiki Biosolutions, Inc.$16.6M
12
BIVIBioVie, Inc.$16.3M
26
AEONAEON Biopharma, Inc.$16.3M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Cerenome, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNSY news & analysis

Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment

GlobeNewsWire · 10 Sept 2026positive

Cerenome announced a senior secured financing facility of up to $20 million with 3i, LP, featuring royalty-based repayments. The initial tranche was provided at closing, with future tranches tied to milestones, and the company said its forecasted cash runway now extends into 2028, with funding supporting the continued commercial scale-up and development of CNSide®.

Why it matters — This financing extends Cerenome's cash runway into 2028 and provides capital to support the commercial scale-up of its CNSide® platform, addressing a key near-term liquidity concern for CNSY watchers.

Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines

GlobeNewsWire · 20 Aug 2026positive

Cerenome highlighted presentations at the 2026 SNO/ASCO CNS Metastases Conference demonstrating progress in both its therapeutics and diagnostics business lines. The data showed REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly leptomeningeal treatment costs by up to 47%.

Why it matters — A CNSY watcher would care because the presentations signal advancement across both the therapeutics and diagnostics businesses, including safety data for REYOBIQ and potential cost savings for CNSide.

Cerenome (CNSY) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Aug 2026negative

Cerenome (CNSY) reported a second-quarter loss of $1.31 per share, wider than the Zacks Consensus Estimate of a $0.96 per-share loss and larger than the $0.25 per-share loss a year earlier, resulting in a miss on revenue estimates.

Why it matters — CNSY watchers would note that the company's quarterly loss came in significantly worse than both analyst expectations and the prior-year period, reflecting deteriorating quarterly performance.

Cerenome Launches as an Integrated CNS Oncology Company

GlobeNewsWire · 31 July 2026neutral

Plus Therapeutics, Inc. announced that its corporate rebrand to Cerenome will be completed as scheduled, with the name change to Cerenome, Inc. effective August 3, 2026. The company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY" at market open that day.

Why it matters — PSTV shareholders should note that the stock will trade under a new ticker symbol (CNSY) and the company will operate under a new name (Cerenome, Inc.) starting August 3, 2026.

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

GlobeNewsWire · 28 July 2026positive

Plus Therapeutics announced that two posters highlighting its ReSPECT-LM clinical development program and CNSide diagnostic platform will be presented at the 2026 SNO/ASCO CNS Metastases Conference, and that the Company and its subsidiary will host a sponsored symposium on redefining the management of leptomeningeal metastases.

Why it matters — A PSTV watcher would care because the presentations and symposium raise the company's visibility in the CNS cancer field and showcase its clinical and diagnostic pipeline at a major industry conference.

FAQ

Frequently asked questions about CNSY stock

What is the CNSY stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Cerenome, Inc. have a median 12-month price target of $38, with estimates ranging from $12 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNSY stock a buy right now?

Of the 4 analysts covering Cerenome, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cerenome, Inc. 17 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNSY?

As at 12 Sept 2026, Cerenome, Inc. ranks 17 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will CNSY stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +1512.9% from the last close, and Ticker Nerd's factor model ranks Cerenome, Inc. 17 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNSY stock forecast for 2030?

No analyst covering Cerenome, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNSY are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $57 over the next 12 months.

How has CNSY stock performed over the past year?

Cerenome, Inc. returned -80.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Cerenome, Inc. do?

Cerenome, Inc. is a clinical-stage biotechnology company focused on central nervous system oncology.

What is the latest news on CNSY?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment". Cerenome announced a senior secured financing facility of up to $20 million with 3i, LP, featuring royalty-based repayments. The initial tranche was provided at closing, with future tranches tied to milestones, and the company said its forecasted cash runway now extends into 2028, with funding supporting the continued commercial scale-up and development of CNSide®.

Company

About Cerenome, Inc.

Cerenome, Inc. is a clinical-stage biotechnology company focused on central nervous system oncology. Cerenome develops precision diagnostics, targeted radiotherapeutics, and data-driven clinical tools designed to support the detection, characterization, and treatment of CNS cancers. Its current portfolio centers on cerebrospinal fluid-based diagnostic testing for monitoring disease in the brain and spinal cord, alongside investigational radiopharmaceutical therapies for conditions such as recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also works with patient data analytics and artificial intelligence to integrate diagnostic and therapeutic insights into a more connected oncology platform. Headquartered in Houston, Texas, Cerenome serves the specialized market for rare and difficult-to-treat CNS malignancies, where its products and programs are positioned within hospital, research, and clinical care settings.

CEO Dr. Marc H. Hedrick M.B.A., M.D. · 28 employees · United States · https://cerenome.com